Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$6.2M
Filings
88
Firms Hired
4
Active Period
2018–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Client expense: $180,000 · Firm income: —
Matched citations: HR 1414
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · third_quarter · Firm: HARMONY BIOSCIENCES
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Client expense: $180,000 · Firm income: —
Matched citations: HR 1492
Maintaining Investments in New Innovation Act
2026 · third_quarter · Firm: HARMONY BIOSCIENCES
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Client expense: $180,000 · Firm income: —
Matched citations: HR 1672
No Big Blockbuster Bailouts Act
2026 · third_quarter · Firm: HARMONY BIOSCIENCES
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Client expense: $180,000 · Firm income: —
Matched citations: S. 3019
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Client expense: $180,000 · Firm income: —
Matched citations: S 832
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Client expense: $180,000 · Firm income: —
Matched citations: HR 1414
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · second_quarter · Firm: HARMONY BIOSCIENCES
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Client expense: $180,000 · Firm income: —
Matched citations: HR 1492
Maintaining Investments in New Innovation Act
2026 · second_quarter · Firm: HARMONY BIOSCIENCES
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Client expense: $180,000 · Firm income: —
Matched citations: HR 1672
No Big Blockbuster Bailouts Act
2026 · second_quarter · Firm: HARMONY BIOSCIENCES
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Client expense: $180,000 · Firm income: —
Matched citations: S. 3019
S. 3019 - No Big Blockbuster Bailouts Act (NOBBBA) Cameron's Law (HR 1414) EPIC Act (HR 1492, S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Client expense: $180,000 · Firm income: —
Matched citations: S 832
Cameron's Law (HR 1414) EPIC Act (HR 1492/S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Client expense: $180,000 · Firm income: —
Matched citations: HR 1414
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · first_quarter · Firm: HARMONY BIOSCIENCES
Cameron's Law (HR 1414) EPIC Act (HR 1492/S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Client expense: $180,000 · Firm income: —
Matched citations: HR 1492
Maintaining Investments in New Innovation Act
2026 · first_quarter · Firm: HARMONY BIOSCIENCES
Cameron's Law (HR 1414) EPIC Act (HR 1492/S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Client expense: $180,000 · Firm income: —
Matched citations: HR 1672
Cameron's Law (HR 1414) EPIC Act (HR 1492/S 832) HR 1672 Maintaining Investments in New Innovation Act Issues related to protecting patient access to medicines Issues related to protecting orphan drug policies Issues related to most-favored-nation policies
Client expense: $180,000 · Firm income: —
Matched citations: S 832
Mikaela Naylon Give Kids a Chance Act
2025 · fourth_quarter · Firm: HARMONY BIOSCIENCES
S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
Client expense: $180,000 · Firm income: —
Matched citations: HR 1262
Maintaining Investments in New Innovation Act
2025 · fourth_quarter · Firm: HARMONY BIOSCIENCES
S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
Client expense: $180,000 · Firm income: —
Matched citations: HR 1672
Innovation in Pediatric Drugs Act of 2025
2025 · fourth_quarter · Firm: HARMONY BIOSCIENCES
S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
Client expense: $180,000 · Firm income: —
Matched citations: S 705
S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
Client expense: $180,000 · Firm income: —
Matched citations: S 832
S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
Client expense: $180,000 · Firm income: —
Matched citations: S 932
Mikaela Naylon Give Kids a Chance Act
2025 · third_quarter · Firm: HARMONY BIOSCIENCES
S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
Client expense: $180,000 · Firm income: —
Matched citations: HR 1262
Maintaining Investments in New Innovation Act
2025 · third_quarter · Firm: HARMONY BIOSCIENCES
S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
Client expense: $180,000 · Firm income: —
Matched citations: HR 1672
Innovation in Pediatric Drugs Act of 2025
2025 · third_quarter · Firm: HARMONY BIOSCIENCES
S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
Client expense: $180,000 · Firm income: —
Matched citations: S 705
S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
Client expense: $180,000 · Firm income: —
Matched citations: S 832
S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
Client expense: $180,000 · Firm income: —
Matched citations: S 932
Mikaela Naylon Give Kids a Chance Act
2025 · second_quarter · Firm: HARMONY BIOSCIENCES
HR 946/ S 1862 ORPHAN Cures Act S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act
Client expense: $150,000 · Firm income: —
Matched citations: HR 1262
Source: Senate LDA